Frequency Therapeutics, Inc. FREQ
At closeNov 3, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 10.94M
- Shares out
- 36.52M
- Forward P/E
- -0.26
- Volume
- 309.16K
- Open
- 0.29
- Previous close
- 0.2996
- Day's range
- 0.28 – 0.32
- Analysts
- Hold
- Price target
- 0.50 (+66.9%)
- Earnings date
- Nov 14, 2023
2Y -6.6204 (-95.67%)
Key statistics
- Enterprise value
- 512.86M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.51M
- Total cash
- 41.72M
- Total debt
- 1.43M
- Return on equity
- -99.93%
- Short % of float
- 1.06%
- 50-day average
- 0.350724
- 200-day average
- 0.639007
Analyst view
Consensus: hold
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 14, 2023
Expected Nov 14, 2023. Consensus EPS estimate -0.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.44 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | -0.39 | — | — | — |
| Mar 10, 2023 | Dec 1, 2022 | -0.65 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -0.61 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -0.69 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2023 | Baird | down | Outperform | Neutral |
| Feb 14, 2023 | Chardan Capital | down | Buy | Neutral |
| Feb 13, 2023 | Oppenheimer | down | Outperform | Perform |
| Feb 13, 2023 | Baird | main | — | Outperform |
| Dec 7, 2022 | Chardan Capital | init | — | Buy |
| Nov 1, 2022 | Baird | init | — | Outperform |
About Frequency Therapeutics, Inc.
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- frequencytx.com
News
Frequency Exchange Announces Appointment Of Friesen To Board Of Directors 
Fremedica Launches Nikki Lyme Wellness Program Through Ergopathics Network 
Frequency Exchange Corp. Appoints Gail Edgell To Advisory Board 
Frequency Exchange Appoints Michael MOE To Advisory Board 
NIKKI's Efficacy in Overcoming Lyme Disease to be Presented at 2024 Leap into Health Conference 
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million 
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million 
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ 
Stocks That Hit 52-Week Lows On Wednesday 
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Your note
Sign in to keep a note on FREQ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD WENDY S | Officer | Sale | Jul 5, 2022 | 21,186 |
| BARBERICH TIMOTHY J | Director | Stock Gift | Dec 23, 2020 | 80,650 |
| LANGER ROBERT S JR. | Director | Stock Gift | Nov 16, 2020 | 240,021 |
| LEBEL CARL | Officer | Sale | Jul 5, 2022 | 26,343 |
| LOOSE CHRISTOPHER R | Officer | Sale | Jul 27, 2023 | 183,650 |
| LUCCHINO DAVID L. | Chief Executive Officer | Sale | Aug 20, 2023 | 633,744 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.73% | 1,727,566 | 597.74K | Jun 29, 2023 |
| Blackrock Inc. | 3.35% | 1,224,091 | 423.54K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 1.12% | 409,200 | 141.58K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.90% | 327,516 | 113.32K | Jun 29, 2023 |
| Gts Securities LLC | 0.61% | 223,278 | 77.25K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 0.39% | 140,945 | 48.77K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.41% | 1,246,700 | 431.36K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.23% | 448,505 | 155.18K | Jun 29, 2023 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.17% | 428,010 | 149.80K | May 30, 2023 |
| BlackRock Health Sciences Term Trust | 0.63% | 231,775 | 80.19K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.51% | 185,128 | 64.79K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.15% | 54,830 | 19.19K | May 30, 2023 |